TScan Therapeutics (NASDAQ:TCRX) Receives Outperform Rating from Wedbush

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock. Wedbush's target price would suggest a potential upside of 37.74% from the stock's previous close.

Separately, HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Stock Up 2.0 %

TScan Therapeutics stock traded up $0.14 during midday trading on Tuesday, reaching $7.26. The stock had a trading volume of 208,208 shares, compared to its average volume of 187,514. The firm's fifty day simple moving average is $7.11 and its 200-day simple moving average is $5.77. TScan Therapeutics has a 1-year low of $1.62 and a 1-year high of $9.00. The stock has a market capitalization of $347.61 million, a P/E ratio of -3.84 and a beta of 0.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. The firm had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. As a group, analysts expect that TScan Therapeutics will post -1.03 EPS for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

A number of institutional investors have recently modified their holdings of the business. abrdn plc acquired a new position in TScan Therapeutics in the 4th quarter worth about $1,166,000. Letko Brosseau & Associates Inc. acquired a new stake in shares of TScan Therapeutics in the third quarter valued at about $83,000. Pale Fire Capital SE increased its stake in shares of TScan Therapeutics by 30.2% in the fourth quarter. Pale Fire Capital SE now owns 21,573 shares of the company's stock valued at $126,000 after buying an additional 4,998 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of TScan Therapeutics in the first quarter valued at about $139,000. Institutional investors and hedge funds own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.